Margin Calculator - Fidelity Investments

$50k AMD shorting loss in 24 hours

$50k AMD shorting loss in 24 hours
Seeing AMD is ATH on Monday, I became greedy yesterday and sold 200 naked calls expiring 814 at $85/$90 hoping the stock will pull back. Tuesday, AMD surged as a huge surprise, which instantly destroyed my buying power. Fidelity called and I had to liquidate for margin call. So $50k loss in 24 hours.
The lesson learned here
  1. Never sell naked calls (although, in this case, it won't help very much as $90 and $95 calls are much cheaper)
  2. Never use too much of your buying power to sell calls, you will likely get margin called if price move against you.
  3. A black swan event or a sudden price change in a stock could bankrupt you. I felt in a way lucky that AMD didn't got to $90 today and remained at $85.
  4. Don't blind yourself P/E ratio, technical analysis on a trendy and passion stock. These don't seem to matter for growth stock anymore.
  5. Be determined when cutting your loss, this morning, I could have limited my loss to $35k when it dipped to $83, but got greedy again and waited a few more minutes and price bounced back to $85.
I'm very unpleased by this outcome, as it's the biggest lost I've had in my trading career, which also wiped out all my gains over the last two months, I hope this would be a good cautionary tale for others.
Edit: I honestly didn't expect this many comments, so just a few reactions to "what I could have done replies":
  1. Rolling the call - I thought about rolling the call to a higher price at later exp date. The upside of this is I won't lose more money than I already lost, but trading off time and security - and the reasonable moves to roll would be in 8/28 or 9/7 but at that time, who knows if AMD will rise to $95-$100 again giving its upcoming PR and new product releases?
  2. Buy the cover when short is ITM - I thought about buying 200 contracts to cover my position, that will restore some of my buying power to avoid liquidation, but these contracts are really expensive now we're talking about $1.9 at $90 to cover $3 at $85, they won't necessarily limit my loss exposure significantly (the reason I didn't buy the cover in the first place), the best case scenario at 8/14 I might only lose $20k, but AMD can keep going up into next week as market index is going up.
  3. Why I believe AMD will keep going up - even AMD by itself at this point is standing still and moving sideway, the macro is going up and things are getting better than I thought, with Friday's bill potentially passing, market can celebrate another 1-2% tech gain and I would be losing another $20-$30k. I also think the chance for AMD to pull back could happen not this week, but next week or late August - based on prior history, in 2018, 2019 AMD both had two long run up streak of %20-%30 gain for more than 2 weeks before pulling back.
I want to thank you all for your support! I'm probably going to slowly play conservative and trade back these losses over the next two months, wish me luck!

https://preview.redd.it/vta2z8sx87f51.png?width=1466&format=png&auto=webp&s=3c797038cd9e09e5cbaa7fd3e9f6dfafc00be5f5
submitted by bwang29 to wallstreetbets [link] [comments]

$LPTH - DD - lightpath technologies - A company which is growing and will keep on growing

Overview: LightPath Technologies is a recognized leader in optics and photonics solutions, serving blue chip customers in the industrial, defense, telecommunications, testing and measurement, and medical industries, for over 35 years. LightPath designs, manufactures, and distributes optical and infrared components including molded glass aspheric lenses and assemblies, infrared lenses and thermal imaging assemblies, and fused fiber collimators.
LightPath also offers custom optical assemblies, including full engineering design support for both optics and mechanics. This allows for the highest level of optical integration, lower cost, and ensures the highest level of quality, performance and manufacturability.
Presence in multiple countries:.
Customers: Look at these customer list, detailed list in the pic. They are separated by Infrared and Visible light. Same can be found HERE

Sector Diversification:
Sector diversification
Infra Red Blue chip customers:
Infra Red Customer list
Visible light Customers:

Visible light Customer list
Products:
Recent News, catalysts, facts:
Results from 3rd quarter results: Link here
Growth: Company uses Chalcogenide and its low cost and very high demand. see this article
Increased mutual fund ownership
Mutual funds have been increasing their positions in LPTH, with previous quarter increases exceeding 48.13% .These funds include Vanguard, Royce, and Fidelity – all moving their positions deeper with Royce now holding 4.4% of the company’s shares. This shows high interest from proven winners who understand the market and a confidence in the long-term profitability of the firm.
https://eresearch.fidelity.com/eresearch/evaluate/fundamentals/ownership.jhtml?stockspage=ownership&symbols=LPTH
Analyst opinions - Refinitiv/Verus has a strong BUY opinion, ranking it with their “SmartIndex” score of 37.41% - a very bullish signal that indicates a strong reasoning to increase positions. This has been upgraded by 3 firms from a Neutral position to a bullish BUY, with FBR indicating a 1-year history of nearly constant outperformance for the relative sector.
Upcoming catalyst: Strong earnings this year, with earnings upcoming September 10th. – Q2 and Q3 have both met or exceeded EPS estimates, with current estimates indicating a repeat of this for the upcoming report. Higher earnings per share is one of the key factors to look at when evaluating the feasibility of any
Price Target: This company has a solid growth. Here is a article which clearly explains thermal imaging market continues to rapidly expand and company has a great future. This is a low float once it gets the eyes it can be move a lot.
Risks:
LPTH has little demonstrated interest in the usual PR-spam that people interested in volatile growth like to see. They focus on their work, and not so much pumping the news cycle. This is both good and bad – when positive PR releases do happen, historical charts show growth is positive and quick – yet the inverse is likely also true. This does also present the benefit of being a safe-haven versus a highly volatile, high volume play.
Relatively low-float – Shares are, by nature, subject to higher volatility and offerings once the prices begin to increase. In companies that stay under the radar such as LPTH, there are opportunities for both buyers and short-sellers, and there is ample opportunity to end up a bag-holder if responsible exit plans are not in place. (This hopefully is becoming a common practice for everyone – know when to leave before you get in!
Stock History: Look at the stock history it has been constantly growing from last 6 month. It was at .63 and now trading around 3$. Its not a pump dump but a company which actually has a growth and a solid investment as well.
submitted by varun22486 to pennystocks [link] [comments]

As a beginner,trading penny stocks has been an arduous journey. How did you improve as a beginner?

My first stock trade ever was Tonix Pharmaceuticals, ticker symbol $TNXP. I put in a market order expecting the stock to rise at least 20%. As it would turn out, $1.50 was the peak of the stocks run and I lost around 30% of my underlying securities value and sold at a huge loss.
My second stock trade was Prona Biotechnology Ltd, ticker symbol $ATHE. I saw it skyrocket during pre-market hours. It was up 150%. Wow! Unfortunately, my broker doesn't allow for pre-market trading at 4 am but rather 7 am. Fine. I then waited until I could put in a limit order for $ATHE and so I did. By the time I looked back, the stock was up 250%. I FOMOed because of the $5 price tag it was now at(it closed at $1.50 the day before).
I believed $ATHE it would go to $7 or so when the market would open because it jumped all the way to $6.15 at pre-market, so i bought at 4.98..... next thing I knew, it's plummeting all the way down to $4.15 five minutes later. I tried selling at a break even point and even put in a limit sell at $5. $ATHE then jumped to $5.75 but there was one problem, MY ORDER NEVER EXECUTED. I don't know why considering the fact my limit order was 5, but that's what happened. I was down 35% the next day(today)and sold at a loss evident of it's current price.
Should I just stop trading penny stocks? I have a relative small account of 300 dollars when comparing to others. Really passionate about trading. What helped you when you were first starting out, its been difficult to trade these penny stocks. What made you improve?
P.S. I'd like to specify how bad a cash account has been. Anyone using Fidelity know the difference between "cash available to trade" and "settled funds"? Charles Schwab gives you margin account when you sign up, even if you don't have 2k. But fidelity makes you wait a week to see you're improved. I was denied, so what's the best course of action here?
Edit: My account has received a trade violation and if I do it one more time, it wont allow me to trade with anything but settled funds for 90 days. I know what this means, but can someone explain more in depths. Specifically the difference between "settled cash" and "cash available to trade"?
submitted by Apennyis1cent to pennystocks [link] [comments]

IBKR Lite 2020 Review

Lemme start by saying I've used several different trading platforms (Robinhood, Merrill Edge, Tastywords, Schwab, TD, Fidelity), and by far IBKR Lite takes the cake in terms of my overall satisfaction. Here's why i think using IBKR Lite is #1 & hope it helps someone out there:
Pros:

Cons:

IBKR Lite Overall Score: 5/5
submitted by Mr_Ready_Finance to interactivebrokers [link] [comments]

Please r/stocks, I have a VERY specific question/situation with account types and what rules apply to them. Thank you!

So when I got approved for margin by accident(never had 2k in my account), I soon got a good faith violation in this margin account by trading with no settled funds all the time, which was unexpected. I thought that you would never have to wait for cash settlements in a margin account. I've been studying days with this but have a VERY important question. I called them but still don't get it.

Here is the question:

I really hope anyone knows the answer to this. Using fidelity, when I go to the trade page to buy or sell a stock, I'm allowed to buy and sell stocks with either "type margin" or "type cash". I always use "type cash" because it says I need 2k for "type margin". Who cares, this isn't the question I mainly have.
Please /stocks! I want to really know this: if I trade with "type margin" I would be working off of margin rules ONLY correct? So if I buy with margin, there would be no good faith violations or free riding right?
And subsequently, if I were to trade with "type cash" would I now be working off of a cash account rules ONLY correct? This means that I could day trade unlimited but with only settled cash? If I buy a stock with "type cash", there would be no PDT rule correct even if I day trade 5 times because when you buy a stock in a margin account with "type cash", you're automatically playing with a cash account again even if you're in a margin account in this instance. When you trade with "type cash" it at least means your trade is based on cash account rules meaning no PDT risk for buying and selling with "type cash" in the margin account. Only risk is getting a good faith violation and free riding violation?
I really want to know the answer to both underlined paragraphs, please. Thank you, it's immensely appreciated! Please don't miss the question, I really need an answer, thank you.
submitted by Apennyis1cent to stocks [link] [comments]

Which brokers offer Trading API ?

Hello, I am looking into automating my trading. Does anyone have experience with online brokers that expose an api for trading ? I currently use Fidelity but I don't see an option except for scripting their web site, which is possible but not ideal for performance. In particular I would need a broker that offers margin trading. Thanks for your help!
submitted by konglongjiqiche to investing [link] [comments]

Best tips for a beginner to use?

What are your tips for a beginner that never traded stocks? Is fidelity a good broker for day trading and swing trading? What is your perspective on this matter? Should you look into options as a beginner, it's really appreciated! And also, should you day trade or swing trading penny stocks? Should you stick with a cash account or go use a margin account?? Thanks!
submitted by Apennyis1cent to Daytrading [link] [comments]

I got a good faith violation on fidelity. Clarification on why??

So i believed that once you get a margin account, good faith violations would not exist ever again and that there would be no such thing as unsettled funds. So I day traded 3 times last monday and traded 5 times in total with no settled funds last week I guess.
When you trade a stock on fidelity, it tells you if you want to trade on "type cash" and or "type margin". Could anyone explain how it works.
Which "type" is PDT applied for and which "type" is free riding and Goof faith violations applied for?
submitted by Apennyis1cent to pennystocks [link] [comments]

Help with margin!! Please r/pennystocks!!

I have been approved for margin in my fidelity account but recently got a good faith violation. I can only trade with settled cash for 90 days.
I have 500 dollars in settled cash and if I do 5 day trades tomorrow with 100 in each day trade(I'm buying stocks with "type cash, not "type margin" on the trade page), is that fine? Will there be any consequence? Please! Thanks, it's appreciated immensely!!
submitted by Apennyis1cent to pennystocks [link] [comments]

$DBVT: DBV Technologies SA

TL; DR: David gives Goliath a run for the money in peanut allergy treatments. May need to hold for a week or two, so no spaghetti hands please.
(Edit: I have also posted this in pennystocks & DueDiligence. Please feel free to comment and share your opinions
DBVT is a clinical-stage biopharmaceutical working on treatments for food allergies. The Company is focused on immunotherapy that works through skin absorption. Market cap. is about $600M.
What the galaxy says:
According to a study done by the Centers for Disease Control (adapted from company website):
The pilots of the ship
The flight guidance system
The stock traded between $8 and $10 pre-covid. It is currently trading around support at $4.5. In fact, the last time it traded around these lows was in December 2018 when the company voluntarily withdrew their BLA application for the Viaskin Peanut product due to “insufficient level of detail about the manufacturing and quality controls”. (Keep in mind, the new CEO joined in November 2018 and he is a thorough man). The price fell from $16 to $4 and they were subsequently sued. The hearing is pending in New Jersey. Previous to this, the price dropped from $42 to $28 in October 2017 when the company announced that the Viaskin Peanut clinical trial failed to achieve statistical significance in the lower end of the 95% confidence interval by a small margin (target was 15%, results indicated 12.4%)
Competitor $AIMT (market cap. $1B) benefited from both of these price moves, but lost the gains as swiftly as they came. In fact, they were unlucky that the approval of their oral tablets for allergy treatment was on January 31st, but they didn’t benefit from the price move due to covid. Furthermore, their drug is priced at $890 per month, only shows benefit after 2 years, and is still dogged by side effects like abdominal pain, vomiting, nausea, tingling in the mouth, itching (including in the mouth and ears), cough, runny nose, throat irritation and tightness, hives, wheezing and shortness of breath and anaphylaxis. This drug must still undergo a Risk Evaluation and Mitigation Strategy (REMS). i.e. it can only be administered in a controlled environment (parents have to take their kids to a certified hospital every 2 weeks) and the administering nurses, doctors and patients all have to register for the REMS.
Wallet situation
In their most recent press release, the company indicated that their cash runway (€262 million) can last through 2021.
The financials are lacklustre. In the past 3 years, revenue has stagnated at around $10M (although they beat estimates). However, since the new CEO was appointed, EPS grew 7% in the first year and 29% in the second year, and they have secured $200M in financing. Not too bad, not too good either, but given the CEO’s strong track record, the good things are yet to come
The rocket fuel
Viaskin technology is currently under review by the FDA. Taget action date for Viaskin Peanut is set for August 5. Viaskin Egg & Viaskin Milk will follow soon after. These products have a US FDA Fast Track designation. You may ask why a French company is developing treatment therapies in the US, and the answer would be that because on average, the process of drug review is 2-3 months faster in the USA than in the EU. If the FDA accepts the test data and gives a way forward on a date for inspection of the manufacturing facilities, then the race for allergy treatments would be blown wide open. It could probably soar back to the $16 range where it was in 2018 before that damned BLA withdrawal, or we can dream about a Saturn landing and aim for $42 where it was in 2017 before the clinical trials failed by the small margin. Nine (9) analysts have given it a short-term price target of $9 and mid-term target of $25, but I like the CEO’s track record and I prefer to dream bigger.
Some other windows to to stargaze
  1. The big boys are in on this one, many since February 2020 and some as recently as June 2020: Baker Brothers (11m shares), Arrowpoint Asset Management (4m), Perceptive Advisors (4M), Boxer Capital (3m), Morgan Stanley (2m), Amundi (1.4m), and Fidelity (574k). Sabby missed this rocket, which makes stargazing all the more beautiful. In total, institutions own 44% of the shares.
  2. There are also also recent acquisitions of stock in (in June 2020) by a number of index funds like FTIHX, IMRFX & JCCIX..
  3. The FDA had questions about the impact of the patch adhesion to its efficacy (remember, no safety issues were reported during the clinical trial). The company has already responded to this query but the FDA has given no further feedback apart from that the data was being reviewed. At this point, it is a coin flip game. High risk, high reward.
  4. The data mentioned in point (iii) above has been published in multiple peer-reviewed scientific publications (this one and this one and this one32155-4/abstract)). All reviews show positive data.
  5. The company recently trimmed down its workforce (something that is notoriously difficult to do in France) and scaled down other clinical programs in order to focus on the Viaskin Peanut product which is coming up for review on August 5th. (This simply indicates that they are very serious about this niche, or that they are prepared for a possible delay of the FDA’s decision)
  6. DBVT is collaborating with Nestlé in a deal worth €100M to develop more product candidates (e.g. Viaskin milk). Nestlé is the largest food company in the world with over 2000 brands and generates $93 billion plus in revenue each year since 2008. However, Nestlé is as notorious as all big companies are, and food allergies have been one of the legal thorns in their flesh for a while. They are personally invested in this peanut allergy product and this collaboration has not been affected by the covid crisis. (Fun fact: Nestle also owns 18% of $AIMT, the competitor company. They are hedging their bets)
  7. Skin patch therapy is potentially more marketable among the market segment that they are targeting (childen & infants) than pills. In addition, they would have potentially less side effects because the active compound gets directly into the bloodstream, and does not get absorbed via the liver.
  8. Consider that it is a French company and the big influence France has in the EU. If they get approved, they might get approval support from the French government too.
submitted by Allegrettoe to PennyDD [link] [comments]

$DBVT: DBV Technologies SA

TL; DR: David gives Goliath a run for the money in peanut allergy treatments. May need to hold for a week or two, so no spaghetti hands please.
(Edit: I have also posted this in PennyDD & DueDiligence. Please feel free to comment and share your opinions
DBVT is a clinical-stage biopharmaceutical working on treatments for food allergies. The Company is focused on immunotherapy that works through skin absorption. Market cap. is about $600M.
What the galaxy says:
According to a study done by the Centers for Disease Control (adapted from company website):
The pilots of the ship
The flight guidance system
The stock traded between $8 and $10 pre-covid. It is currently trading around support at $4.5. In fact, the last time it traded around these lows was in December 2018 when the company voluntarily withdrew their BLA application for the Viaskin Peanut product due to “insufficient level of detail about the manufacturing and quality controls”. (Keep in mind, the new CEO joined in November 2018 and he is a thorough man). The price fell from $16 to $4 and they were subsequently sued. The hearing is pending in New Jersey. Previous to this, the price dropped from $42 to $28 in October 2017 when the company announced that the Viaskin Peanut clinical trial failed to achieve statistical significance in the lower end of the 95% confidence interval by a small margin (target was 15%, results indicated 12.4%)
Competitor $AIMT (market cap. $1B) benefited from both of these price moves, but lost the gains as swiftly as they came. In fact, they were unlucky that the approval of their oral tablets for allergy treatment was on January 31st, but they didn’t benefit from the price move due to covid. Furthermore, their drug is priced at $890 per month, only shows benefit after 2 years, and is still dogged by side effects like abdominal pain, vomiting, nausea, tingling in the mouth, itching (including in the mouth and ears), cough, runny nose, throat irritation and tightness, hives, wheezing and shortness of breath and anaphylaxis. This drug must still undergo a Risk Evaluation and Mitigation Strategy (REMS). i.e. it can only be administered in a controlled environment (parents have to take their kids to a certified hospital every 2 weeks) and the administering nurses, doctors and patients all have to register for the REMS.
Wallet situation
In their most recent press release, the company indicated that their cash runway (€262 million) can last through 2021.
The financials are lacklustre. In the past 3 years, revenue has stagnated at around $10M (although they beat estimates). However, since the new CEO was appointed, EPS grew 7% in the first year and 29% in the second year, and they have secured $200M in financing. Not too bad, not too good either, but given the CEO’s strong track record, the good things are yet to come
The rocket fuel
Viaskin technology is currently under review by the FDA. Taget action date for Viaskin Peanut is set for August 5. Viaskin Egg & Viaskin Milk will follow soon after. These products have a US FDA Fast Track designation. You may ask why a French company is developing treatment therapies in the US, and the answer would be that because on average, the process of drug review is 2-3 months faster in the USA than in the EU. If the FDA accepts the test data and gives a way forward on a date for inspection of the manufacturing facilities, then the race for allergy treatments would be blown wide open. It could probably soar back to the $16 range where it was in 2018 before that damned BLA withdrawal, or we can dream about a Saturn landing and aim for $42 where it was in 2017 before the clinical trials failed by the small margin. Nine (9) analysts have given it a short-term price target of $9 and mid-term target of $25, but I like the CEO’s track record and I prefer to dream bigger.
Some other windows to to stargaze
  1. The big boys are in on this one, many since February 2020 and some as recently as June 2020: Baker Brothers (11m shares), Arrowpoint Asset Management (4m), Perceptive Advisors (4M), Boxer Capital (3m), Morgan Stanley (2m), Amundi (1.4m), and Fidelity (574k). Sabby missed this rocket, which makes stargazing all the more beautiful. In total, institutions own 44% of the shares.
  2. There are also also recent acquisitions of stock in (in June 2020) by a number of index funds like FTIHX, IMRFX & JCCIX..
  3. The FDA had questions about the impact of the patch adhesion to its efficacy (remember, no safety issues were reported during the clinical trial). The company has already responded to this query but the FDA has given no further feedback apart from that the data was being reviewed. At this point, it is a coin flip game. High risk, high reward.
  4. The data mentioned in point (iii) above has been published in multiple peer-reviewed scientific publications (this one and this one and this one32155-4/abstract)). All reviews show positive data.
  5. The company recently trimmed down its workforce (something that is notoriously difficult to do in France) and scaled down other clinical programs in order to focus on the Viaskin Peanut product which is coming up for review on August 5th. (This simply indicates that they are very serious about this niche, or that they are prepared for a possible delay of the FDA’s decision)
  6. DBVT is collaborating with Nestlé in a deal worth €100M to develop more product candidates (e.g. Viaskin milk). Nestlé is the largest food company in the world with over 2000 brands and generates $93 billion plus in revenue each year since 2008. However, Nestlé is as notorious as all big companies are, and food allergies have been one of the legal thorns in their flesh for a while. They are personally invested in this peanut allergy product and this collaboration has not been affected by the covid crisis. (Fun fact: Nestle also owns 18% of $AIMT, the competitor company. They are hedging their bets)
  7. Skin patch therapy is potentially more marketable among the market segment that they are targeting (childen & infants) than pills. In addition, they would have potentially less side effects because the active compound gets directly into the bloodstream, and does not get absorbed via the liver.
  8. Consider that it is a French company and the big influence France has in the EU. If they get approved, they might get approval support from the French government too.
submitted by Allegrettoe to pennystocks [link] [comments]

[ITG] This Skytech Shadow Gaming Desktop for gaming? (Details inside)

The prebuilt in question - from Best Buy.
Before I begin, please pardon my ignorance. This is all quite confusing for me and I'm trying to be as concise as possible to get my thoughts out.
I'm looking for a PC for general gaming - I like mainly RPGs (Mass Effect, Fallout: New Vegas, Elder Scrolls) chock-full of mods. I also play a lot of FPS (Halo, Borderlands, general shooters).
I don't know if this build has what I need to run some of these games I'm looking for. I'm just kind of a general gamer, I just play whatever so I'm looking for kind of a jack-of-all-trades - nothing specific, but something that can run most games decently.
I'm not absolutely obsessed with frames - I'm willing to sacrifice frames for that graphical fidelity, you understand? If I can get both, then better.
Is the above listed a good, general purpose gaming PC? Is there something much better for a marginal price increase? Any other notes or points you would like to make?
Thanks in advance!
submitted by PresidentJoe to suggestapc [link] [comments]

Do not be jealous if your balance didn't x10 in a week.

Okay I admit it. I am one of the guys who x30 (or even more) his account balances, from the initial less than 1k cash deposited into my account less than 3 weeks ago. But the story that I don't like to tell people is that I have been ridden to shit from the gambling attitude, borrowed money from friends and poured every paycheck into my trading account, lived on overdue credit cards, got margin called and banned from trading on margin by fidelity because I blew my money to ashes, from my original more than 30k cash account, I rode it up to 6 figures only to burn it down to the fucking ground. Gambled my 3 years away, got fucked in the ass with it, and decided to throw a final card in only 3 weeks ago. And I was just lucky, with some changes to my attitude, to make it here. And now I am at the point where I started 3 years ago, inflation-adjusted and hypothetically if I had put money into just a regular index fund/ETF instead, I'm still losing out.
I'm not going to make the same mistake. The most important lesson I've learned throughout my years is that taking profit is the crucial part of investing. It's the consistent game, psychological game, where you must not let winning or losing get into your head, but to make the right decision. Well yeah, fuck it if you don't double your money in one day, or if you don't make 10 out of 10 right calls. The only thing that matters is that you consistently make money, and your balance consistently goes up, if that's the case, then all is good. Opportunities are always there, but your money might be not. Keep some cash at hands, and remember profit is profit. Your wife's boyfriend is gonna be proud.

Edit: I'm gay don't ban me. I'd suck your dick for free
submitted by cocoaflavorbutthole to wallstreetbets [link] [comments]

Buying Power/Fractional Trading/Pending Transfers

I have a question about buying stock while a transfer is pending. After I initially set up my account, I initiate a transfer of money from my bank account to my Fidelity account. Before that money deposited/transferred, I was able to buy shares with that amount of money. I've attempted to do this again and I'm unable to. My margin/non-margin is at 0, but my "buying power" is at the amount that is pending transfer.
I've contacted Fidelity but the representative that picked up the phone wasn't able to provide much information and put in a ticket. He indicated this may have something to do specifically with fractional trading via the app (and that it would likely work with full shares, but he didn't sound confident, and I'm not buying full shares), and that he is showing I have the referenced amount in buying power, currently.
I'm curious if anyone here can provide some insight. Why was I able to buy fractional shares via the app with my first pending transfer, but not with this order?
submitted by Piccolo_Alone to Fidelity [link] [comments]

$DBVT: DBV Technologies SA

TL; DR: David gives Goliath a run for the money in peanut allergy treatments. May need to hold for a week or two, so no spaghetti hands please.
(Edit: I have also posted this in pennystocks & PennyDD. Please feel free to comment and share your opinions
DBVT is a clinical-stage biopharmaceutical working on treatments for food allergies. The Company is focused on immunotherapy that works through skin absorption. Market cap. is about $600M.
What the galaxy says:
According to a study done by the Centers for Disease Control (adapted from company website):
The pilots of the ship
The flight guidance system
The stock traded between $8 and $10 pre-covid. It is currently trading around support at $4.5. In fact, the last time it traded around these lows was in December 2018 when the company voluntarily withdrew their BLA application for the Viaskin Peanut product due to “insufficient level of detail about the manufacturing and quality controls”. (Keep in mind, the new CEO joined in November 2018 and he is a thorough man). The price fell from $16 to $4 and they were subsequently sued. The hearing is pending in New Jersey. Previous to this, the price dropped from $42 to $28 in October 2017 when the company announced that the Viaskin Peanut clinical trial failed to achieve statistical significance in the lower end of the 95% confidence interval by a small margin (target was 15%, results indicated 12.4%)
Competitor $AIMT (market cap. $1B) benefited from both of these price moves, but lost the gains as swiftly as they came. In fact, they were unlucky that the approval of their oral tablets for allergy treatment was on January 31st, but they didn’t benefit from the price move due to covid. Furthermore, their drug is priced at $890 per month, only shows benefit after 2 years, and is still dogged by side effects like abdominal pain, vomiting, nausea, tingling in the mouth, itching (including in the mouth and ears), cough, runny nose, throat irritation and tightness, hives, wheezing and shortness of breath and anaphylaxis. This drug must still undergo a Risk Evaluation and Mitigation Strategy (REMS). i.e. it can only be administered in a controlled environment (parents have to take their kids to a certified hospital every 2 weeks) and the administering nurses, doctors and patients all have to register for the REMS.
Wallet situation
In their most recent press release, the company indicated that their cash runway (€262 million) can last through 2021.
The financials are lacklustre. In the past 3 years, revenue has stagnated at around $10M (although they beat estimates). However, since the new CEO was appointed, EPS grew 7% in the first year and 29% in the second year, and they have secured $200M in financing. Not too bad, not too good either, but given the CEO’s strong track record, the good things are yet to come
The rocket fuel
Viaskin technology is currently under review by the FDA. Taget action date for Viaskin Peanut is set for August 5. Viaskin Egg & Viaskin Milk will follow soon after. These products have a US FDA Fast Track designation. You may ask why a French company is developing treatment therapies in the US, and the answer would be that because on average, the process of drug review is 2-3 months faster in the USA than in the EU. If the FDA accepts the test data and gives a way forward on a date for inspection of the manufacturing facilities, then the race for allergy treatments would be blown wide open. It could probably soar back to the $16 range where it was in 2018 before that damned BLA withdrawal, or we can dream about a Saturn landing and aim for $42 where it was in 2017 before the clinical trials failed by the small margin. Nine (9) analysts have given it a short-term price target of $9 and mid-term target of $25, but I like the CEO’s track record and I prefer to dream bigger.
Some other windows to to stargaze
  1. The big boys are in on this one, many since February 2020 and some as recently as June 2020: Baker Brothers (11m shares), Arrowpoint Asset Management (4m), Perceptive Advisors (4M), Boxer Capital (3m), Morgan Stanley (2m), Amundi (1.4m), and Fidelity (574k). Sabby missed this rocket, which makes stargazing all the more beautiful. In total, institutions own 44% of the shares.
  2. There are also also recent acquisitions of stock in (in June 2020) by a number of index funds like FTIHX, IMRFX & JCCIX..
  3. The FDA had questions about the impact of the patch adhesion to its efficacy (remember, no safety issues were reported during the clinical trial). The company has already responded to this query but the FDA has given no further feedback apart from that the data was being reviewed. At this point, it is a coin flip game. High risk, high reward.
  4. The data mentioned in point (iii) above has been published in multiple peer-reviewed scientific publications (this one and this one and this one32155-4/abstract)). All reviews show positive data.
  5. The company recently trimmed down its workforce (something that is notoriously difficult to do in France) and scaled down other clinical programs in order to focus on the Viaskin Peanut product which is coming up for review on August 5th. (This simply indicates that they are very serious about this niche, or that they are prepared for a possible delay of the FDA’s decision)
  6. DBVT is collaborating with Nestlé in a deal worth €100M to develop more product candidates (e.g. Viaskin milk). Nestlé is the largest food company in the world with over 2000 brands and generates $93 billion plus in revenue each year since 2008. However, Nestlé is as notorious as all big companies are, and food allergies have been one of the legal thorns in their flesh for a while. They are personally invested in this peanut allergy product and this collaboration has not been affected by the covid crisis. (Fun fact: Nestle also owns 18% of $AIMT, the competitor company. They are hedging their bets)
  7. Skin patch therapy is potentially more marketable among the market segment that they are targeting (childen & infants) than pills. In addition, they would have potentially less side effects because the active compound gets directly into the bloodstream, and does not get absorbed via the liver.
  8. Consider that it is a French company and the big influence France has in the EU. If they get approved, they might get approval support from the French government too.
submitted by Allegrettoe to DueDiligence [link] [comments]

I really need clarification on what is going on with my margin account. Do cash account rules apply (VERY SPECIFIC)

So when I got approved for margin by accident(never had 2k in my account), I soon got a good faith violation in this margin account by trading with no settled funds all the time, which was unexpected. I thought that you would never have to wait for cash settlements in a margin account. I've been studying days with this but have a VERY important question. I called them but still don't get it.
Here is the question: I really hope anyone knows the answer to this. Using fidelity, when I go to the trade page to buy or sell a stock, I'm allowed to buy and sell stocks with either "type margin" or "type cash". I always use "type cash" because it says I need 2k for "type margin". Who cares, this isn't the question I mainly have.
Please /stocks! I want to really know this: if I trade with "type margin" I would be working off of margin rules ONLY correct? So if I buy with margin, there would be no good faith violations or free riding right? And subsequently, if I were to trade with "type cash" would I now be working off of a cash account rules ONLY correct? This means that I could day trade unlimited but with only settled cash? If I buy a stock with "type cash", there would be no PDT rule correct even if I day trade 5 times because when you buy a stock in a margin account with "type cash", you're automatically playing with a cash account again even if you're in a margin account in this instance. When you trade with "type cash" it at least means your trade is based on cash account rules meaning no PDT risk for buying and selling with "type cash" in the margin account. Only risk is getting a good faith violation and free riding violation? I really want to know the answer to both underlined paragraphs, please. Thank you, it's immensely appreciated! Please don't miss the question, I really need an answer, thank you.
submitted by Apennyis1cent to stocks [link] [comments]

Which broker would you pick today?

So I've been using eTrade for several years now along with Fidelity for my trading. Mostly eTrade for my daytrading activity. Playing with around $30k in capital and using margin. I'm not really committed to either. I'll keep my long-term 401k/HSA/IRA investments sitting at Fidelity (but that is not actively traded) but want to consolidate by active trading and daytrading so now is a good time for me to find a new broker.
I was tempted to just go with TDA and the ThinkOrSwim platform. But then someone suggested I look at Interactive Brokers and their TWS platform and another review suggested TradeStation.
My question is if you were starting from scratch - meaning you didn't already know a platform deep - which would you want to start with today?
My hesitation with TDA/ThinkOrSwim is that I've seen multiple folks, including on this subreddit, complaining about execution time. Since I do daytrading that does matter - although it'll probably still be better than eTrade.
submitted by goatofeverything to Daytrading [link] [comments]

Goof faith violations

I guess I’m a little confused that I’ve received 2 in the last few weeks. I understand what GFVs are and how they work. I have a cash account with fidelity. The thing I find odd is, I definitely bought and sold in the same day with no issues in the past. So maybe I’m misunderstanding something here. My question is, if I have more than enough “cash to trade” in my account when selling a stock before funds are settled, would that avoid a GFV? If I have enough cash deposited to cover the cost of what I bought and then sold, before the transaction was settled, then I’m ok to sell before the funds for that specific transaction are settled? Any help is appreciated. If I’m wrong here, what are the options to avoid GFVs besides have a min balance of 25k lol? Margin account? Thanks!
submitted by Saso-1 to stocks [link] [comments]

I have a really important question about Fidelity. It's immensely appreciated.

I have 2 really important question and it's immensely appreciated whoever knows what this is about, here goes:
I logged into my Fidelity account today and Margin columns randomly appeared in my balance section and when I go to trade a stock. I've got a small account of 300 dollars and applied for margin and options a few weeks back and was messaged I was denied. I then resubmitted an application over a week ago and today randomly saw margin columns everywhere. I never received messages or any notification from Fidelity stating I was approved or denied. Why is this? Is my account a Margin account now or is it still a cash account? Is this normal?
Now begs question 2: Since I was on my cash account, I received a violation recently. I believe it was a free ride or GVF but not sure but was told I if I did it again, that I would only allowed to trade with settled funds.
So looking at this now, I day traded a stock yesterday with all my settled funds. I then bought new stocks today with the proceeds I got from the sell(I believe the cash from the day trade never settled). I know I can't sell because I did not used "settled funds" but rather "cash available to trade". But does this not matter anymore since margin columns appeared on my account, can I trade it now without it being settled funds?? What does this mean? I I still have no settled funds.
Margin columns appeared on my UI, does this mean the cash account is gone? What's going on with this?? Thank you in advance, it's appreciated.
submitted by Apennyis1cent to pennystocks [link] [comments]

Crypto Banking Wars: Will Coinbase or Binance Become The Bank of The Future?

Crypto Banking Wars: Will Coinbase or Binance Become The Bank of The Future?
Can the early success of major crypto exchanges propel them to winning the broader consumer finance market?
https://reddit.com/link/i48t4q/video/v4eo10gom7f51/player
This is the first part of Crypto Banking Wars — a new series that examines what crypto-native company is most likely to become the bank of the future. Who is best positioned to reach mainstream adoption in consumer finance?
While crypto allows the world to get rid of banks, a bank will still very much be necessary for this powerful technology to reach the masses. We believe a crypto-native company, like Genesis Block, will become the bank of the future.
In an earlier series, Crypto-Powered, we laid out arguments for why crypto-native companies have a huge edge in the market. When you consider both the broad spectrum of financial use-cases and the enormous value unlocked through these DeFi protocols, you can see just how big of an unfair advantage blockchain tech becomes for companies who truly understand and leverage it. Traditional banks and fintech unicorns simply won’t be able to keep up.
The power players of consumer finance in the 21st century will be crypto-native companies who build with blockchain technology at their core.
The crypto landscape is still nascent. We’re still very much in the fragmented, unbundled phase of the industry lifecycle. Beyond what Genesis Block is doing, there are signs of other companies slowly starting to bundle financial services into what could be an all-in-one bank replacement.
So the key question that this series hopes to answer:
Which crypto-native company will successfully become the bank of the future?
We obviously think Genesis Block is well-positioned to win. But we certainly aren’t the only game in town. In this series, we’ll be doing an analysis of who is most capable of thwarting our efforts. We’ll look at categories like crypto exchanges, crypto wallets, centralized lending & borrowing services, and crypto debit card companies. Each category will have its own dedicated post.
Today we’re analyzing big crypto exchanges. The two companies we’ll focus on today are Coinbase (biggest American exchange) and Binance (biggest global exchange). They are the top two exchanges in terms of Bitcoin trading volume. They are in pole position to winning this market — they have a huge existing userbase and strong financial resources.
Will Coinbase or Binance become the bank of the future? Can their early success propel them to winning the broader consumer finance market? Is their growth too far ahead for anyone else to catch up? Let’s dive in.
https://preview.redd.it/lau4hevpm7f51.png?width=800&format=png&auto=webp&s=2c5de1ba497199f36aa194e5809bd86e5ab533d8

Binance

The most formidable exchange on the global stage is Binance (Crunchbase). All signs suggest they have significantly more users and a stronger balance sheet than Coinbase. No other exchange is executing as aggressively and relentlessly as Binance is. The cadence at which they are shipping and launching new products is nothing short of impressive. As Tushar Jain from Multicoin argues, Binance is Blitzscaling.
Here are some of the products that they’ve launched in the last 18 months. Only a few are announced but still pre-launch.
Binance is well-positioned to become the crypto-powered, all-in-one, bundled solution for financial services. They already have so many of the pieces. But the key question is:
Can they create a cohesive & united product experience?

Binance Weaknesses

Binance is strong, but they do have a few major weaknesses that could slow them down.
  1. Traders & Speculators Binance is currently very geared for speculators, traders, and financial professionals. Their bread-and-butter is trading (spot, margin, options, futures). Their UI is littered with depth charts, order books, candlesticks, and other financial concepts that are beyond the reach of most normal consumers. Their product today is not at all tailored for the broader consumer market. Given Binance’s popularity and strength among the pro audience, it’s unlikely that they will dumb down or simplify their product any time soon. That would jeopardize their core business. Binance will likely need an entirely new product/brand to go beyond the pro user crowd. That will take time (or an acquisition). So the question remains, is Binance even interested in the broader consumer market? Or will they continue to focus on their core product, the one-stop-shop for pro crypto traders?
  2. Controversies & Hot Water Binance has had a number of controversies. No one seems to know where they are based — so what regulatory agencies can hold them accountable? Last year, some sensitive, private user data got leaked. When they announced their debit card program, they had to remove mentions of Visa quickly after. And though the “police raid” story proved to be untrue, there are still a lot of questions about what happened with their Shanghai office shut down (where there is smoke, there is fire). If any company has had a “move fast and break things” attitude, it is Binance. That attitude has served them well so far but as they try to do business in more regulated countries like America, this will make their road much more difficult — especially in the consumer market where trust takes a long time to earn, but can be destroyed in an instant. This is perhaps why the Binance US product is an empty shell when compared to their main global product.
  3. Disjointed Product Experience Because Binance has so many different teams launching so many different services, their core product is increasingly feeling disjointed and disconnected. Many of the new features are sloppily integrated with each other. There’s no cohesive product experience. This is one of the downsides of executing and shipping at their relentless pace. For example, users don’t have a single wallet that shows their balances. Depending on if the user wants to do spot trading, margin, futures, or savings… the user needs to constantly be transferring their assets from one wallet to another. It’s not a unified, frictionless, simple user experience. This is one major downside of the “move fast and break things” approach.
  4. BNB token Binance raised $15M in a 2017 ICO by selling their $BNB token. The current market cap of $BNB is worth more than $2.6B. Financially this token has served them well. However, given how BNB works (for example, their token burn), there are a lot of open questions as to how BNB will be treated with US security laws. Their Binance US product so far is treading very lightly with its use of BNB. Their token could become a liability for Binance as it enters more regulated markets. Whether the crypto community likes it or not, until regulators get caught up and understand the power of decentralized technology, tokens will still be a regulatory burden — especially for anything that touches consumers.
  5. Binance Chain & Smart Contract Platform Binance is launching its own smart contract platform soon. Based on compatibility choices, they have their sights aimed at the Ethereum developer community. It’s unclear how easy it’ll be to convince developers to move to Binance chain. Most of the current developer energy and momentum around smart contracts is with Ethereum. Because Binance now has their own horse in the race, it’s unlikely they will ever decide to leverage Ethereum’s DeFi protocols. This could likely be a major strategic mistake — and hubris that goes a step too far. Binance will be pushing and promoting protocols on their own platform. The major risk of being all-in on their own platform is that they miss having a seat on the Ethereum rocket ship — specifically the growth of DeFi use-cases and the enormous value that can be unlocked. Integrating with Ethereum’s protocols would be either admitting defeat of their own platform or competing directly against themselves.

Binance Wrap Up

I don’t believe Binance is likely to succeed with a homegrown product aimed at the consumer finance market. Their current product — which is focused heavily on professional traders and speculators — is unlikely to become the bank of the future. If they wanted to enter the broader consumer market, I believe it’s much more likely that they will acquire a company that is getting early traction. They are not afraid to make acquisitions (Trust, JEX, WazirX, DappReview, BxB, CoinMarketCap, Swipe).
However, never count CZ out. He is a hustler. Binance is executing so aggressively and relentlessly that they will always be on the shortlist of major contenders.
https://preview.redd.it/mxmlg1zqm7f51.png?width=800&format=png&auto=webp&s=2d900dd5ff7f3b00df5fe5a48305d57ebeffaa9a

Coinbase

The crypto-native company that I believe is more likely to become the bank of the future is Coinbase (crunchbase). Their dominance in America could serve as a springboard to winning the West (Binance has a stronger foothold in Asia). Coinbase has more than 30M users. Their exchange business is a money-printing machine. They have a solid reputation as it relates to compliance and working with regulators. Their CEO is a longtime member of the crypto community. They are rumored to be going public soon.

Coinbase Strengths

Let’s look at what makes them strong and a likely contender for winning the broader consumer finance market.
  1. Different Audience, Different Experience Coinbase has been smart to create a unique product experience for each audience — the pro speculator crowd and the common retail user. Their simple consumer version is at Coinbase.com. That’s the default. Their product for the more sophisticated traders and speculators is at Coinbase Pro (formerly GDAX). Unlike Binance, Coinbase can slowly build out the bank of the future for the broad consumer market while still having a home for their hardcore crypto traders. They aren’t afraid to have different experiences for different audiences.
  2. Brand & Design Coinbase has a strong product design team. Their brand is capable of going beyond the male-dominated crypto audience. Their product is clean and simple — much more consumer-friendly than Binance. It’s clear they spend a lot of time thinking about their user experience. Interacting directly with crypto can sometimes be rough and raw (especially for n00bs). When I was at Mainframe we hosted a panel about Crypto UX challenges at the DevCon4 Dapp Awards. Connie Yang (Head of Design at Coinbase) was on the panel. She was impressive. Some of their design philosophies will bode well as they push to reach the broader consumer finance market.
  3. USDC Stablecoin Coinbase (along with Circle) launched USDC. We’ve shared some stats about its impressive growth when we discussed DeFi use-cases. USDC is quickly becoming integrated with most DeFi protocols. As a result, Coinbase is getting a front-row seat at some of the most exciting things happening in decentralized finance. As Coinbase builds its knowledge and networks around these protocols, it could put them in a favorable position to unlock incredible value for their users.
  4. Early Signs of Bundling Though Coinbase has nowhere near as many products & services as Binance, they are slowly starting to add more financial services that may appeal to the broader market. They are now letting depositors earn interest on USDC (also DAI & Tezos). In the UK they are piloting a debit card. Users can now invest in crypto with dollar-cost-averaging. It’s not much, but it’s a start. You can start to see hints of a more bundled solution around financial services.

Coinbase Weaknesses

Let’s now look at some things that could hold them back.
  1. Slow Cadence In the fast-paced world of crypto, and especially when compared to Binance, Coinbase does not ship very many new products very often. This is perhaps their greatest weakness. Smaller, more nimble startups may run circles around them. They were smart to launch Coinbase Ventures where tey invest in early-stage startups. They can now keep an ear to the ground on innovation. Perhaps their cadence is normal for a company of their size — but the Binance pace creates quite the contrast.
  2. Lack of Innovation When you consider the previous point (slow cadence), it’s unclear if Coinbase is capable of building and launching new products that are built internally. Most of their new products have come through acquisitions. Their Earn.com acquisition is what led to their Earn educational product. Their acquisition of Xapo helped bolster their institutional custody offering. They acqui-hired a team to help launch their staking infrastructure. Their acquisition of Cipher Browser became an important part of Coinbase Wallet. And recently, they acquired Tagomi — a crypto prime brokerage. Perhaps most of Coinbase’s team is just focused on improving their golden goose, their exchange business. It’s unclear. But the jury is still out on if they can successfully innovate internally and launch any homegrown products.
  3. Talent Exodus There have been numerous reports of executive turmoil at Coinbase. It raises a lot of questions about company culture and vision. Some of the executives who departed include COO Asiff Hirji, CTO Balaji Srinivasan, VP & GM Adam White, VP Eng Tim Wagner, VP Product Jeremy Henrickson, Sr Dir of Eng Namrata Ganatra, VP of Intl Biz Dan Romero, Dir of Inst Sales Christine Sandler, Head of Trading Hunter Merghart, Dir Data Science Soups Ranjan, Policy Lead Mike Lempres, Sr Compliance Vaishali Mehta. Many of these folks didn’t stay with Coinbase very long. We don’t know exactly why it’s happening —but when you consider a few of my first points (slow cadence, lack of innovation), you have to wonder if it’s all related.
  4. Institutional Focus As a company, we are a Coinbase client. We love their institutional offering. It’s clear they’ve been investing a lot in this area. A recent Coinbase blog post made it clear that this has been a focus: “Over the past 12 months, Coinbase has been laser-focused on building out the types of features and services that our institutional customers need.” Their Tagomi acquisition only re-enforced this focus. Perhaps this is why their consumer product has felt so neglected. They’ve been heavily investing in their institutional services since May 2018. For a company that’s getting very close to an IPO, it makes sense that they’d focus on areas that present strong revenue opportunities — as they do with institutional clients. Even for big companies like Coinbase, it’s hard to have a split focus. If they are “laser-focused” on the institutional audience, it’s unlikely they’ll be launching any major consumer products anytime soon.

Coinbase Wrap Up

At Genesis Block, we‘re proud to be working with Coinbase. They are a fantastic company. However, I don’t believe that they’ll succeed in building their own product for the broader consumer finance market. While they have incredible design, there are no signs that they are focused on or capable of internally building this type of product.
Similar to Binance, I think it’s far more likely that Coinbase acquires a promising young startup with strong growth.

Honorable Mentions

Other US-based exchanges worth mentioning are Kraken, Gemini, and Bittrex. So far we’ve seen very few signs that any of them will aggressively attack broader consumer finance. Most are going in the way of Binance — listing more assets and adding more pro tools like margin and futures trading. And many, like Coinbase, are trying to attract more institutional customers. For example, Gemini with their custody product.

Wrap Up

Coinbase and Binance have huge war chests and massive reach. For that alone, they should always be considered threats to Genesis Block. However, their products are very, very different than the product we’re building. And their approach is very different as well. They are trying to educate and onboard people into crypto. At Genesis Block, we believe the masses shouldn’t need to know or care about it. We did an entire series about this, Spreading Crypto.
Most everyone needs banking — whether it be to borrow, spend, invest, earn interest, etc. Not everyone needs a crypto exchange. For non-crypto consumers (the mass market), the differences between a bank and a crypto exchange are immense. Companies like Binance and Coinbase make a lot of money on their crypto exchange business. It would be really difficult, gutsy, and risky for any of them to completely change their narrative, messaging, and product to focus on the broader consumer market. I don’t believe they would ever risk biting the hand that feeds them.
In summary, as it relates to a digital bank aimed at the mass market, I believe both Coinbase and Binance are much more likely to acquire a startup in this space than they are to build it themselves. And I think they would want to keep the brand/product distinct and separate from their core crypto exchange business.
So back to the original question, is Coinbase and Binance a threat to Genesis Block? Not really. Not today. But they could be, and for that, we want to stay close to them.
------
Other Ways to Consume Today's Episode:
Follow our social channels: https://genesisblock.com/follow/
Download the app. We're a digital bank that's powered by crypto: https://genesisblock.com/download
submitted by mickhagen to genesisblockhq [link] [comments]

Does anyone here use Fidelity? I have a really important question about accounts to ask.

I have 2 really important question and it's immensely appreciated whoever knows what this is about, here goes:
I logged into my Fidelity account today and Margin columns randomly appeared in my balance section and when I go to trade a stock. I've got a small account of 300 dollars and applied for margin and options a few weeks back and was messaged I was denied. I then resubmitted an application over a week ago and today randomly saw margin columns everywhere. I never received messages or any notification from Fidelity stating I was approved or denied. Why is this? Is my account a Margin account now or is it still a cash account? Is this normal?
Now begs question 2: Since I was on my cash account, I received a violation recently. I believe it was a free ride or GVF but not sure but was told I if I did it again, that I would only allowed to trade with settled funds.
So looking at this now, I day traded a stock yesterday with all my settled funds. I then bought new stocks today with the proceeds I got from the sell(I believe the cash from the day trade never settled). I know I can't sell because I did not used "settled funds" but rather "cash available to trade". But does this not matter anymore since margin columns appeared on my account, can I trade it now without it being settled funds?? What does this mean? I I still have no settled funds.
Margin columns appeared on my UI, does this mean the cash account is gone? What's going on with this?? Thank you in advance, it's appreciated.
submitted by Apennyis1cent to stocks [link] [comments]

Are Roth IRAs limited margin on webull?

Tired of dealing with good faith violations on fidelity. PDT doesn't bother me on margin with my trading style.
submitted by Bull_Logic to Webull [link] [comments]

How to Trade With Fidelity  Active Trader Pro ... How do you trade ETFs?  Fidelity Trading in Active Trader Pro  Fidelity - YouTube Robinhood to Fidelity-Why a Margin? How to trade options on Fidelity - YouTube

A margin credit indicates the amount due to you based on margin trade executions or an amount needed to meet margin requirements. On settlement date, this amount would be journaled to your Core if there is surplus in the Margin account. A margin debit indicates the amount you owe Fidelity based on margin trade executions. Using your own money, you could purchase 1,000 shares at $30 per share. If you use margin, you can increase the number of shares you can buy. Let’s say you buy 1,500 shares. At this point your total portfolio with margin would be $45,000, instead of the $30,000 you could’ve bought with just your money. A margin loan from Fidelity is interest-bearing and can be used to gain access to funds for a variety of needs that cover both investment and non-investment needs. Margin borrowing can be used to satisfy short-term liquidity needs similar to how you may use a home equity line of credit or to buy more securities than you could on a cash-only basis. A margin loan from Fidelity is interest-bearing and can be used to gain access to funds for a variety of needs that cover both investment and non-investment needs. Margin borrowing can be used to satisfy short-term liquidity needs similar to how you may use a home equity line of credit or to buy more securities than you could on a cash-only basis. Fidelity's current base margin rate is 7.075%. Margin trading entails greater risk, including, but not limited to, risk of loss and incurrence of margin interest debt, and is not suitable for all investors. Please assess your financial circumstances and risk tolerance before trading on margin. Margin credit is extended by National Financial ...

[index] [68] [860] [160] [924] [816] [967] [752] [580] [656] [991]

How to Trade With Fidelity Active Trader Pro ...

New investors, beware! Make sure you know what your account is set at. https://myincomejob.com https://storebuy.shop Buy Gas Receive Cash Back - GetUpSide - https://upside.app.link/YUJED WeBull ... Beginner's tutorial on how to place your first options trade using Fidelity or most other brokerages. Also includes tips on basic option trading terminology ... Learn to leverage Active Trader Pro's single, multi-trade, and directed trading capabilities to enhance your investing experience. Find out more about tradin... Beginner's tutorial on how to set up a brokerage account and place your first stock, mutual fund, or ETF trade using Fidelity or most other brokerages. Also ... Follow me on Tik Tok: https://vm.tiktok.com/p3GNDU/ Follow me on Instagram: https://www.instagram.com/therealmatthewgperry/ Matthew G Perry Store: https://ww...

#